Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
| ▸ | ADH5 | P11766 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 5/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950027 | 0.90 | TDP1 (0.39) | SRD5A2GRIA4ACLYPTGS1KDM4E | |
| SCHEMBL4950640 | 0.89 | KDM4E (0.43) | SRD5A2GRIA4POLBACLYPTGS1 | |
| SCHEMBL4950718 | 0.88 | RARB (0.41) | GRIA4ADH5ADRB1ADRB3PTGS1 | |
| SCHEMBL4945608 | 0.86 | TDP1 (0.43) | POLBADRB1ADRB3ACLYPTGS1 | |
| SCHEMBL4953693 | 0.85 | GRIA4 (0.49) | SRD5A2GRIA4ACLYPTGS1KDM4E | |
| SCHEMBL4952509 | 0.85 | TDP1 (0.37) | SRD5A2GRIA4ADRB1ADRB3ACLY | |
| SCHEMBL4949007 | 0.85 | GRM5 (0.36) | GRIA4PTGS1KDM4ETDP1 | |
| SCHEMBL252191 | 0.83 | TSHR (0.42) | SRD5A2GRIA4POLBPTGS1TTR | |
| SCHEMBL27703688 | 0.83 | TTR (0.41) | GRIA4POLBACLYTTRKDM4E | |
| SCHEMBL4952472 | 0.82 | F11 (0.35) | GRIA4PTGS1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893597-B1 | AMPA RECEPTOR POTENTIATORS | LILLY CO ELI (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7393868-B2 | AMPA receptor potentiators | ELI LILLY AND COMPANY (US) | 2008-07-01 | — | — | US | disclosed |
| US-20070142441-A1 | AMPA receptor potentiators | ELI LILLY AND COMPANY | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142441-A1 | AMPA receptor potentiators | GABRE, GRIN1, GRIK2 | SRD5A2 3003/4885GRIA4 41/4885ADH5 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.